Carlsmed opened higher at $18.77, compared with its previous close of $18.60. In the last trading session, the stock traded between $17.95 and $19.00. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Carlsmed is now worth
$ 119.76
Giving a profit of
$ 19.76 (19.76%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.24 (-6.64%)
Day High
$19.00
Day Low
$17.95
Day Open
$18.77
Prev Close
$18.60
Volume
3,50,898
1W Return
8.23%
1M Return
17.73%
3M Return
26.66%
6M Return
79.76%
1Y Return
42.57%
Fundamentals
Market Cap ($ Mn)
476
PE Ratio
-
PB Ratio
5.46
PEG Ratio
-
ROE
-
ROCE
-41.09%
EPS (TTM)
-
Investment Returns
1 Week
8.23%
1 Month
17.73%
3 Months
26.66%
6 Months
79.76%
9 Months
52.06%
Financials
Quarterly
All values in $ Mn
10.2
Mar 25
12.1
Jun 25
13.1
Sep 25
15.2
Dec 25
16.1
Mar 26
18.9
Jun 26
Updates
11Nov
BTIG raises Carlsmed price target to $26, maintains Buy rating
BTIG analyst Ryan Zimmerman raised the price target on Carlsmed to $26. The new target represents a $2 increase from the previous $24 level. The firm maintained its Buy rating on the stock.
Yesterday
11Nov
Carlsmed Q3FY26 Results: Adj. EPS beats estimate, revenue up 65%
Revenue rose 65% YoY to $21.554 million, beating consensus estimates by 12.53%. Adjusted EPS of $(0.34) outperformed the analyst estimate of $(0.40). Full-year revenue guidance raised to $78-$80 million range. Gross margin expanded 140 bps to 77.3% due to manufacturing efficiencies.
2 days ago
14Oct
Carlsmed launches aprevo Lumbar Bi-lateral Posterior System in US
Carlsmed launched the aprevo® Lumbar Bi-lateral Posterior System in the US. Launch occurred during the NASS 41st Annual Meeting in San Antonio. Follows first in-human procedure completed on February 10, 2026. System supports direct posterior approach for personalized spine fusion.
29 days ago
3Oct
Carlsmed grants equity to new CFO and Chief Product Officer
Carlsmed granted 180,137 stock options and 89,286 RSUs to new CFO Richard Heppenstall. New Chief Product and AI Officer Anthony Jarc received 132,464 options and 63,735 RSUs. Grants were approved by the Compensation Committee as inducements under Nasdaq Rule 5635(c)(4). Options vest over four years while RSUs vest in three annual installments.
1mo ago
28Sep
Carlsmed FY26 Results: Sales guidance affirmed at $74-78 million
Carlsmed affirms FY2026 sales guidance of $74.000 million to $78.000 million. The guidance range is unchanged from prior disclosures. Analyst consensus estimate stands at $74.830 million.
1mo ago
16Sep
Carlsmed sues DeGen Medical over eight spine surgery patents
Carlsmed sued DeGen Medical on Sept. 15, 2026. Lawsuit filed in South Carolina federal court. Allegations cover eight spine surgery patents. Claims include implants, methods, and systems. Company seeks injunctive relief and damages.
